Bausch Health (Bausch Health) Cash And Cash Equivalents : $947 Mil (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Bausch Health Cash And Cash Equivalents?

Bausch Health's quarterly cash and cash equivalents increased from Jun. 2023 ($579.00 Mil) to Sep. 2023 ($760.00 Mil) and increased from Sep. 2023 ($760.00 Mil) to Dec. 2023 ($947.00 Mil).

Bausch Health's annual cash and cash equivalents declined from Dec. 2021 ($582.00 Mil) to Dec. 2022 ($564.00 Mil) but then increased from Dec. 2022 ($564.00 Mil) to Dec. 2023 ($947.00 Mil).

Bausch Health Cash And Cash Equivalents Historical Data

The historical data trend for Bausch Health's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Cash And Cash Equivalents Chart

Bausch Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

3,243.00

605.00

582.00

564.00

947.00

Bausch Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															564.00	518.00	579.00	760.00	947.00

Bausch Health Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Bausch Health (NYSE:BHC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Bausch Health Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bausch Health's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch Health (Bausch Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BVF:Germany BVF:Germany BHC:Canada

Address

2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8

Website

https://www.bauschhealth.com

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Executives

Seana Carson	officer: EVP, General Counsel	400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi	officer: SVP, Controller & CAO	727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan	director	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh	officer: EVP, Chief Financial Officer	1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr	director, officer: U.S. President-Pharma Business	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon	officer: Pres&Co-Head Bausch&Lomb/Int'l	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch	officer: SVP, Controller and CAO	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann	officer: EVP AND GENERAL COUNSEL	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky	officer: EVP & Chief Financial Officer	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller	director	16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries	officer: EVP, COMPANY GROUP CHAIRMAN	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p.	director, other: See remarks	ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129